{"organizations": [], "uuid": "cf5135a353c3f4bb5dd30dc137bd451bee11380e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180425.html", "section_title": "Archive News &amp; Video for Wednesday, 25 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-entasis-therapeutics-and-zai-lab-a/brief-entasis-therapeutics-and-zai-lab-announce-exclusive-license-agreement-in-asia-pacific-and-global-strategic-development-collaboration-for-etx2514-idUSFWN1S20RM", "country": "US", "domain_rank": 408, "title": "BRIEF-Entasis Therapeutics And Zai Lab Announce Exclusive License Agreement In Asia-Pacific And Global Strategic Development Collaboration For ETX2514", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.023, "site_type": "news", "published": "2018-04-25T20:08:00.000+03:00", "replies_count": 0, "uuid": "cf5135a353c3f4bb5dd30dc137bd451bee11380e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-entasis-therapeutics-and-zai-lab-a/brief-entasis-therapeutics-and-zai-lab-announce-exclusive-license-agreement-in-asia-pacific-and-global-strategic-development-collaboration-for-etx2514-idUSFWN1S20RM", "ord_in_thread": 0, "title": "BRIEF-Entasis Therapeutics And Zai Lab Announce Exclusive License Agreement In Asia-Pacific And Global Strategic Development Collaboration For ETX2514", "locations": [], "entities": {"persons": [{"name": "entasis", "sentiment": "none"}], "locations": [{"name": "asia-pacific", "sentiment": "none"}, {"name": "china", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "zai lab ltd", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 25 (Reuters) - Zai Lab Ltd:\n* ENTASIS THERAPEUTICS AND ZAI LAB ANNOUNCE EXCLUSIVE LICENSE AGREEMENT IN ASIA-PACIFIC AND GLOBAL STRATEGIC DEVELOPMENT COLLABORATION FOR ETX2514\n* ZAI LAB LTD - COLLABORATION WILL FACILITATE ENROLLMENT OF GLOBAL PHASE 3 TRIAL OF ETX2514 IN COMBINATION WITH SULBACTAM\n* ZAI LAB LTD - ZAI LAB WILL MANAGE PORTION OF PHASE 3 TRIAL CONDUCTED IN CHINA\n* ZAI LAB LTD - ETX2514SUL IS CURRENTLY IN PHASE 2 DEVELOPMENT WITH PLANS TO MOVE INTO GLOBAL PHASE 3 CLINICAL TRIALS IN Q1 OF 2019\n* ZAI LAB LTD - ENTASIS AND CO HAVE AN OPTION TO COLLABORATE ON DEVELOPMENT, COMMERCIALIZATION OF ETX2514 IN COMBINATION WITH OTHER ACTIVE INGREDIENTS\n* ZAI LAB - ENTASIS WILL RECEIVE A $5 MILLION UPFRONT PAYMENT, ELIGIBLE FOR UP TO $91 MILLION IN MILESTONE PAYMENTS RELATED TO ETX2514SUL, OTHER COMBINATIONS Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-25T20:08:00.000+03:00", "crawled": "2018-04-26T20:21:40.000+03:00", "highlightTitle": ""}